Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury

Toxicology Letters

Volumn 228, Issue 1, 2014, Pages 13-24

  Yano, Azusa ^a   Oda, Shingo ^a,b   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a,b  

^a KANAZAWA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell based assay; Drug metabolism; Drug induced liver injury; Immune reaction; Inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; ANTIBODY; ASPARTATE AMINOTRANSFERASE; CRYOPYRIN; CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKEMIA CELL; LIVER TOXICITY; METABOLIC ACTIVATION; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TOXIC HEPATITIS;

CELL-BASED ASSAY; DRUG METABOLISM; DRUG-INDUCED LIVER INJURY; IMMUNE REACTION; INFLAMMATION;

ADJUVANTS, IMMUNOLOGIC; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MICE; MICE, INBRED BALB C; PHARMACEUTICAL PREPARATIONS; REAL-TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TUMOR CELLS, CULTURED;

EID: 84899788299     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.04.005     Document Type: Article

References (50)

1. Antoine D.J., Williams D.P., Kipar A., Jenkins R.E., Regan S.L., Sathish J.G., Kitteringham N.R., Park B.K. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 2009, 112:521-531.
2. Antoine D.J., Williams D.P., Kipar A., Laverty H., Park B.K. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol. Med. 2010, 16:479-490.
3. Baillie T.A. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1988, 1:195-199.
4. Bryant C., Fitzgerald K.A. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol. 2009, 19:455-464.
5. Cheng L., You Q., Yin H., Holt M.P., Ju C. Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem. Pharmacol. 2010, 80:255-261.
6. Craig D.G., Lee P., Pryde E.A., Masterton G.S., Hayes P.C., Simpson K.J. Circulating apoptotic and necrotic cell death markers in patients with acute liver injury. Liver Int. 2011, 31:1127-1136.
7. Deng X., Liguori M.J., Sparkenbaugh E.M., Waring J.F., Blomme E.A., Ganey P.E., Roth R.A. Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury. J. Pharmacol. Exp. Ther. 2008, 327:634-644.
8. Deng X., Stachlewitz R.F., Liguori M.J., Blomme E.A., Waring J.F., Luyendyk J.P., Maddox J.F., Ganey P.E., Roth R.A. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 2006, 319:1191-1199.
9. Dugan C.M., Fullerton A.M., Roth R.A., Ganey P.E. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol. Sci. 2011, 120:507-518.
10. Dugan C.M., MacDonald A.E., Roth R.A., Ganey P.E. A mouse model of severe halothane hepatitis based on human risk factors. J. Pharmacol. Exp. Ther. 2010, 333:364-372.
11. Physicians' Desk Reference 2004, Thomson Healthcare Inc., Montvale, NJ. D. Duplay (Ed.).
12. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17:3-16.
13. Gole W. Physicians' Desk Reference 1995, Medical Economics Co., Montvale, NJ.
14. Hess D.A., Rieder M.J. The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann. Pharmacother. 1997, 31:1378-1387.
15. Higuchi S., Kobayashi M., Yano A., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. J. Appl. Toxicol. 2012, 32:815-822.
16. Higuchi S., Kobayashi M., Yoshikawa Y., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol. Lett. 2011, 200:139-145.
17. Higuchi S., Yano A., Takai S., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol. Sci. 2012, 130:4-16.
18. Imaeda A.B., Watanabe A., Sohail M.A., Mahmood S., Mohamadnejad M., Sutterwala F.S., Flavell R.A., Mehal W.Z. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 2009, 119:305-314.
19. Ishida Y., Kondo T., Tsuneyama K., Lu P., Takayasu T., Mukaida N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J. Leukocyte Biol. 2004, 75:59-67.
20. Kita H., Mackay I.R., Van De Water J., Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001, 120:1485-1501.
21. Kobayashi E., Kobayashi M., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 2009, 111:302-310.
22. Kobayashi Y., Fukami T., Higuchi R., Nakajima M., Yokoi T. Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem. Pharmacol. 2012, 84:1196-1206.
23. Latz E. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 2010, 22:28-33.
24. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003, 349:474-485.
25. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., Devera M.E., Liang X., Tör M., Billiar T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 2007, 220:60-81.
26. Lu W., Uetrecht J.P. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab. Dispos. 2008, 36:1624-1636.
27. Maher J.J. DAMPs ramp up drug toxicity. J. Clin. Invest. 2009, 119:246-249.
28. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
29. Mizuno K., Toyoda Y., Fukami T., Nakajima M., Yokoi T. Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Arch. Toxicol. 2011, 85:199-207.
30. Nakayama S., Atsumi R., Takakusa H., Kobayashi Y., Kurihara A., Nagai Y., Nakai D., Okazaki O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 2009, 37:1970-1977.
31. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
32. Oo Y.H., Adams D.H. The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 2010, 34:45-54.
33. Racanelli V., Rehermann B. The liver as an immunological organ. Hepatology 2006, 43:S54-S62.
34. Ramaiah S.K., Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol. Pathol. 2007, 35:757-766.
35. Sanborn K. Physicians' Desk Reference 2008, Thomson Healthcare Inc., Montvale, NJ.
36. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
37. Spahn-Langguth H., Benet L.Z. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?. Drug Metab. Rev. 1992, 24:5-47.
38. Takakusa H., Masumoto H., Yukinaga H., Makino C., Nakayama S., Okazaki O., Sudo K. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab. Dispos. 2008, 36:1770-1779.
39. Tukov F.F., Luyendyk J.P., Ganey P.E., Roth R.A. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol. Sci. 2007, 100:267-280.
40. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the danger hypothesis and innate immune system. Chem. Res. Toxicol. 1999, 12:387-395.
41. Uetrecht J.P. Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions?. Curr. Drug Metab. 2000, 1:133-141.
42. Usui T., Mise M., Hashizume T., Yabuki M., Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 2009, 37:2383-2392.
43. Walgren J.L., Mitchell M.D., Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 2005, 35:325-361.
44. Physicians' Desk Reference 2000, Medical Economics Co., Montvale, NJ. P. Walsh (Ed.).
45. Wang H., Yang H., Tracey K.J. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 2004, 255:320-331.
46. Yano A., Higuchi S., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Toxicology 2012, 293:107-114.
47. Yao D., Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249-255.
48. You Q., Cheng L., Reilly T.P., Wegmann D., Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006, 44:1421-1431.
49. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11:136-140.
50. Zou W., Roth R.A., Younis H.S., Burgoon L.D., Ganey P.E. Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology 2010, 272:32-38.